Enabling Streamlined Formulation Development of Amorphous Solid Dispersion Drug Products

***Live: Thursday, January 28, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** Amorphous solid dispersions (ASDs) are a critical technology for bioavailability enhancement. In this webcast Lonza’s Deanna Mudie and Aaron Stewart discuss Lonza’s best practices for ASD formulation development and in vitro testing.*** On demand available after final airing until Jan. 28, 2022.***